Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease

Patients with type 2 diabetes are at high risk of adverse cardiovascular and renal outcomes. Diabetic kidney disease is the most frequent cause of mortality and morbidity, leading a global health burden. The treatment of diabetes is rapidly changing and several new therapeutic agents have been released in the past decade.Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin and canagliflozin, have been widely used as anti-diabetic drugs. Recent clinical studies have demonstrated that these drugs, which improve glycemic control and hypertension and decrease body weight, decrease the risk of renal function impairment and heart failure in patients with type 2 diabetes.
Source: Journal of Diabetes and Its Complications - Category: Endocrinology Authors: Tags: Review article Source Type: research